Skip to main content
Erschienen in: Drugs & Aging 11/2016

24.09.2016 | Original Research Article

Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II)

verfasst von: Dominik Spira, Jeremy Walston, Nikolaus Buchmann, Jivko Nikolov, Ilja Demuth, Elisabeth Steinhagen-Thiessen, Rahel Eckardt, Kristina Norman

Erschienen in: Drugs & Aging | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Pharmacological options for the treatment of sarcopenia currently do not exist. However, off-label treatment options of some established drugs have been suggested.

Objectives

The aim of this study was to assess differences in various muscle and physical performance parameters in relation to the intake of angiotensin-converting enzyme (ACE) inhibitors in a cohort of community-dwelling older people.

Methods

Eight hundred and thirty-eight participants from the Berlin Aging Study-II (BASE-II) were included. Appendicular lean mass was assessed with dual-energy X-ray absorptiometry and related to height and body mass index. Muscle strength was measured by grip strength and related to muscle mass (arm muscle quality) and functional status was assessed via the timed “Up and Go” test.

Results

Users of ACE inhibitors had higher lean mass related to height but significantly lower lean mass related to body mass index (p = 0.001 for women and p < 0.0001 for men). Moreover, they exhibited lower arm muscle quality (p = 0.032 for women and p = 0.031 for men) and reported difficulties in climbing stairs more often than non-users (p = 0.014 for women and p = 0.004 for men). After adjustment for confounders, there were no significant differences regarding lean mass, arm muscle quality and the timed “Up and Go” test according to the use of ACE inhibitors.

Conclusions

In BASE-II, no positive relationship was found between the intake of ACE inhibitors and lean mass, strength, muscle quality or function. Moreover, remarkable differences between parameters of absolute and relative lean mass in relation to the use of ACE inhibitors became evident. Fat mass proved to be an important confounder and therefore muscle mass cannot be viewed irrespectively of whole body composition.
Literatur
1.
Zurück zum Zitat Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European Consensus on Definition and Diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.CrossRefPubMedPubMedCentral Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European Consensus on Definition and Diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Janssen HC, Emmelot-Vonk MH, Verhaar HJ, et al. Determinants of vitamin D status in healthy men and women aged 40–80 years. Maturitas. 2013;74:79–83.CrossRefPubMed Janssen HC, Emmelot-Vonk MH, Verhaar HJ, et al. Determinants of vitamin D status in healthy men and women aged 40–80 years. Maturitas. 2013;74:79–83.CrossRefPubMed
3.
Zurück zum Zitat Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56.CrossRefPubMed Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56.CrossRefPubMed
4.
Zurück zum Zitat Rolland Y, Onder G, Morley JE, et al. Current and future pharmacologic treatment of sarcopenia. Clin Geriatr Med. 2011;27(3):423–47.CrossRefPubMed Rolland Y, Onder G, Morley JE, et al. Current and future pharmacologic treatment of sarcopenia. Clin Geriatr Med. 2011;27(3):423–47.CrossRefPubMed
5.
Zurück zum Zitat Garg R, Yusuf S, Bussmann WD. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273(18):1450–6.CrossRefPubMed Garg R, Yusuf S, Bussmann WD. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273(18):1450–6.CrossRefPubMed
6.
Zurück zum Zitat Parmley WW. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med. 1998;105(1A):27S–31S.CrossRefPubMed Parmley WW. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med. 1998;105(1A):27S–31S.CrossRefPubMed
7.
Zurück zum Zitat Onder G, Vedova CD, Pahor M. Effects of ACE inhibitors on skeletal muscle. Curr Pharm Des. 2006;12(16):2057–64.CrossRefPubMed Onder G, Vedova CD, Pahor M. Effects of ACE inhibitors on skeletal muscle. Curr Pharm Des. 2006;12(16):2057–64.CrossRefPubMed
8.
Zurück zum Zitat Sumukadas D, Witham MD, Struthers AD, et al. ACE inhibitors as a therapy for sarcopenia: evidence and possible mechanisms. J Nutr Health Aging. 2008;12(7):480–5.CrossRefPubMed Sumukadas D, Witham MD, Struthers AD, et al. ACE inhibitors as a therapy for sarcopenia: evidence and possible mechanisms. J Nutr Health Aging. 2008;12(7):480–5.CrossRefPubMed
9.
Zurück zum Zitat Di Bari M, van de Poll-Franse LV, Onder G, et al. Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2004;52(6):961–6.CrossRefPubMed Di Bari M, van de Poll-Franse LV, Onder G, et al. Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2004;52(6):961–6.CrossRefPubMed
10.
Zurück zum Zitat Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002;359(9310):926–30.CrossRefPubMed Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002;359(9310):926–30.CrossRefPubMed
11.
Zurück zum Zitat Schaufelberger M, Andersson G, Eriksson BO, et al. Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. Eur Heart J. 1996;17(11):1678–85.CrossRefPubMed Schaufelberger M, Andersson G, Eriksson BO, et al. Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. Eur Heart J. 1996;17(11):1678–85.CrossRefPubMed
12.
Zurück zum Zitat Cesari M, Pedone C, Incalci RA, et al. ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. J Am Med Dir Assoc. 2010;11(1):26–32.CrossRefPubMed Cesari M, Pedone C, Incalci RA, et al. ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. J Am Med Dir Assoc. 2010;11(1):26–32.CrossRefPubMed
13.
Zurück zum Zitat Sumukadas D, Witham MD, Struthers AD, et al. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. Can Med Assoc J. 2007;177(8):867–74.CrossRef Sumukadas D, Witham MD, Struthers AD, et al. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. Can Med Assoc J. 2007;177(8):867–74.CrossRef
14.
Zurück zum Zitat Sumukadas D, Band M, Miller S, et al. Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2014;69(6):736–43.CrossRefPubMed Sumukadas D, Band M, Miller S, et al. Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2014;69(6):736–43.CrossRefPubMed
15.
Zurück zum Zitat McLean RR, Shardell MD, Alley DE, et al. Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. J Gerontol A Biol Sci Med Sci. 2014;69(5):576–83.CrossRefPubMedPubMedCentral McLean RR, Shardell MD, Alley DE, et al. Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. J Gerontol A Biol Sci Med Sci. 2014;69(5):576–83.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Bertram L, Böckenhoff A, Demuth I, et al. Cohort profile: the Berlin Aging Study II (BASE-II). Int J Epidemiol. 2014;43(3):703–12.CrossRefPubMed Bertram L, Böckenhoff A, Demuth I, et al. Cohort profile: the Berlin Aging Study II (BASE-II). Int J Epidemiol. 2014;43(3):703–12.CrossRefPubMed
17.
Zurück zum Zitat Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–63.CrossRefPubMed Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–63.CrossRefPubMed
18.
Zurück zum Zitat Cawthon PM, Peters KW, Shardell MD, et al. Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014;69(5):567–75.CrossRefPubMedPubMedCentral Cawthon PM, Peters KW, Shardell MD, et al. Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014;69(5):567–75.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–57.CrossRefPubMed Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–57.CrossRefPubMed
20.
Zurück zum Zitat Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the Health, Aging, and Body Composition Study. Diabetes. 2006;55(6):1813–8.CrossRefPubMed Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the Health, Aging, and Body Composition Study. Diabetes. 2006;55(6):1813–8.CrossRefPubMed
21.
Zurück zum Zitat Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.CrossRefPubMed Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.CrossRefPubMed
22.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
23.
Zurück zum Zitat Gerstorf D, Hulur G, Drewelies J, et al. Secular changes in late-life cognition and well-being: towards a long bright future with a short brisk ending? Psychol Aging. 2015;30(2):301–10.CrossRefPubMed Gerstorf D, Hulur G, Drewelies J, et al. Secular changes in late-life cognition and well-being: towards a long bright future with a short brisk ending? Psychol Aging. 2015;30(2):301–10.CrossRefPubMed
24.
Zurück zum Zitat Estrada M, Kleppinger A, Judge JO, et al. Functional impact of relative versus absolute sarcopenia in healthy older women. J Am Geriatr Soc. 2007;55(11):1712–9.CrossRefPubMed Estrada M, Kleppinger A, Judge JO, et al. Functional impact of relative versus absolute sarcopenia in healthy older women. J Am Geriatr Soc. 2007;55(11):1712–9.CrossRefPubMed
25.
Zurück zum Zitat Bijlsma AY, Meskers CGM, van den Eshof N, et al. Diagnostic criteria for sarcopenia and physical performance. Age. 2014;36(1):275–85.CrossRefPubMed Bijlsma AY, Meskers CGM, van den Eshof N, et al. Diagnostic criteria for sarcopenia and physical performance. Age. 2014;36(1):275–85.CrossRefPubMed
26.
Zurück zum Zitat Spira D, Buchmann N, Nikolov J, et al. Association of low lean mass with frailty and physical performance: a comparison between two operational definitions of sarcopenia. Data from the Berlin Aging Study II (BASE-II). J Gerontol A Biol Sci Med Sci. 2015;70(6):779–84.CrossRefPubMed Spira D, Buchmann N, Nikolov J, et al. Association of low lean mass with frailty and physical performance: a comparison between two operational definitions of sarcopenia. Data from the Berlin Aging Study II (BASE-II). J Gerontol A Biol Sci Med Sci. 2015;70(6):779–84.CrossRefPubMed
27.
Zurück zum Zitat Sternfeld B, Ngo L, Satariano WA, et al. Associations of body composition with physical performance and self-reported functional limitation in elderly men and women. Am J Epidemiol. 2002;156(2):110–21.CrossRefPubMed Sternfeld B, Ngo L, Satariano WA, et al. Associations of body composition with physical performance and self-reported functional limitation in elderly men and women. Am J Epidemiol. 2002;156(2):110–21.CrossRefPubMed
28.
Zurück zum Zitat Dufour AB, Hannan MT, Murabito JM, et al. Sarcopenia definitions considering body size and fat mass are associated with mobility limitations: the Framingham Study. J Gerontol A Biol Sci Med Sci. 2013;68(2):168–74.CrossRefPubMed Dufour AB, Hannan MT, Murabito JM, et al. Sarcopenia definitions considering body size and fat mass are associated with mobility limitations: the Framingham Study. J Gerontol A Biol Sci Med Sci. 2013;68(2):168–74.CrossRefPubMed
29.
Zurück zum Zitat Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting enzyme inhibitors: an observational study. Lancet. 2003;361(9363):1077–83.CrossRefPubMed Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting enzyme inhibitors: an observational study. Lancet. 2003;361(9363):1077–83.CrossRefPubMed
30.
Zurück zum Zitat Gray SL, Aragaki AK, LaMonte MJ, et al. Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc. 2012;60(12):2206–14.CrossRefPubMedPubMedCentral Gray SL, Aragaki AK, LaMonte MJ, et al. Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc. 2012;60(12):2206–14.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Witham MD, Syddall HE, Dennison E, et al. ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study. Age Ageing. 2014;43(5):661–6.CrossRefPubMed Witham MD, Syddall HE, Dennison E, et al. ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study. Age Ageing. 2014;43(5):661–6.CrossRefPubMed
32.
Zurück zum Zitat Zhou Ls Xu, Lj Wang XQ, et al. Effect of angiotensin-converting enzyme inhibitors on physical function in elderly subjects: a systematic review and meta-analysis. Drugs Aging. 2015;32(9):727–35.CrossRefPubMed Zhou Ls Xu, Lj Wang XQ, et al. Effect of angiotensin-converting enzyme inhibitors on physical function in elderly subjects: a systematic review and meta-analysis. Drugs Aging. 2015;32(9):727–35.CrossRefPubMed
33.
Zurück zum Zitat Farquharson CAJ, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol. 2002;39(5):767–75.CrossRefPubMed Farquharson CAJ, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol. 2002;39(5):767–75.CrossRefPubMed
34.
Zurück zum Zitat Cichello SA, Weisinger RS, Schuijers J, et al. 1-Sarcosine-angiotensin II infusion effects on food intake, weight loss, energy expenditure, and skeletal muscle UCP3 gene expression in a rat model. J Cachexia Sarcopenia Muscle. 2014;5(3):239–46.CrossRefPubMedPubMedCentral Cichello SA, Weisinger RS, Schuijers J, et al. 1-Sarcosine-angiotensin II infusion effects on food intake, weight loss, energy expenditure, and skeletal muscle UCP3 gene expression in a rat model. J Cachexia Sarcopenia Muscle. 2014;5(3):239–46.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Brink M, Price SR, Chrast J, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology. 2001;142(4):1489–96.PubMed Brink M, Price SR, Chrast J, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology. 2001;142(4):1489–96.PubMed
36.
Zurück zum Zitat Sumukadas D, Struthers AD, McMurdo MET. Sarcopenia: a potential target for angiotensin-converting enzyme inhibition? Gerontology. 2006;52(4):237–42.CrossRefPubMed Sumukadas D, Struthers AD, McMurdo MET. Sarcopenia: a potential target for angiotensin-converting enzyme inhibition? Gerontology. 2006;52(4):237–42.CrossRefPubMed
Metadaten
Titel
Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II)
verfasst von
Dominik Spira
Jeremy Walston
Nikolaus Buchmann
Jivko Nikolov
Ilja Demuth
Elisabeth Steinhagen-Thiessen
Rahel Eckardt
Kristina Norman
Publikationsdatum
24.09.2016
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 11/2016
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-016-0396-8

Weitere Artikel der Ausgabe 11/2016

Drugs & Aging 11/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.